Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$195.88M$195.88M+20.8% vs Q1 2023 Net Income$76.82M$76.82M+93.9% vs Q1 2023 EPS Diluted$0.60$0.60+106.9% vs Q1 2023 Operating Income$95,542,000+77.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Free Cash Flowderived$125,882,000+66.5% Margins · derivedOperating margin48.8%+15.6 pt vs Q1 2023
Net margin39.2%+14.8 pt vs Q1 2023
ended Mar 31, 2024 · filed May 7, 2024 · 37 d after period end